Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Oral Oncology|June 10, 2018
Comparative genomic analysis of oral versus laryngeal and pharyngeal cancerDavid M Vossen, Caroline V M Verhagen, Marcel Verheij, et al.
Oncotarget|September 1, 2018
DNA Repair Molecular Beacon assay: a platform for real-time functional analysis of cellular DNA repair capacityJianfeng Li, David Svilar, Steven McClellan, et al.
Oncogene|June 26, 2002
Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrestPierre-Marie Girard, Enriqueta Riballo, Adrian C Begg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 22, 2016
Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the glandGhazaleh Ghobadi, Jeroen de Jong, Birgit G Hollmann, et al.
Cancers|September 9, 2022
Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision OncologyAlexander M A van der Wiel, Lesley Schuitmaker, Ying Cong, et al.
International Journal of Radiation Oncology, Biology, Physics|September 28, 2011
5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cellsSofie F Isebaert, Johannes V Swinnen, William H McBride, et al.
Clinical and Translational Radiation Oncology|November 29, 2023
Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinomaArash Navran, Abrahim Al-Mamgani, Hester Elzinga, et al.
Plos One|November 9, 2018
Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint associationDavid M Vossen, Caroline V M Verhagen, Reidar Grénman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 19, 2017
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trialsRosemarie de Haan, Dick Pluim, Baukelien van Triest, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 19, 2015
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cellsCaroline V M Verhagen, Rosemarie de Haan, Floor Hageman, et al.
Pageof 8